We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Sequencer Designed to Drive Advances in Cancer Biology and Genetic Disease Research

By LabMedica International staff writers
Posted on 25 Nov 2010
Print article
A new sequencer is designed to provide very fast and accurate genomic data for cancer biology and genetic disease research.

Life Technologies Corp. (Carlsbad, CA, USA), a provider of life science solutions, announced the launch of the 5500xl SOLiD sequencer. Developed and manufactured with long-standing partner Hitachi High-Technologies Corp. (Tokyo, Japan), the 5500xl delivers on the promise of the SOLiD 4hq, which was first announced in January 2010.

"We are delighted to be a partner of the joint development and manufacturing of the 5500 and 5500xl SOLiD sequencers. The 5500xl represents a significant leap forward in next-generation sequencing,” said Mark Stevenson, chief operating officer for Life Technologies. "We have revolutionized the biggest arsenal in our sequencing portfolio by evolving the instrument and the chemistries to better address the needs of translational researchers. Its unprecedented accuracy and rapid throughput make the 5500xl the ideal sequencing instrument for deciphering the genetic code of cancer, and paving the way for the future development of sequencing technologies for eventual use in clinical settings.”

The 5500xl SOLiD sequencer enables high-quality basepair format data--the new Exact Call Chemistry (ECC) option enables single-read accuracy better than 99.99%. These high-accuracy data are essential for the detection of minor variants in heterogeneous samples, a critical area of importance in cancer research. Furthermore, the data output is in standard base-pair format, allowing easier interface with third-party tertiary data analysis tools.

The 5500xl SOLiD sequencer utilizes a novel rapid-scan fluorescence detection system and it will initially deliver 20 Gb/day to 30 Gb/day of DNA sequence. Two high quality human genomes, 24 whole exomes, or 12 whole transcriptomes can be processed in a single run. With high-density nanobead technology, planned for the second half of 2011, the system will deliver 30 Gb/day to 45 Gb/day, increasing capacity to three or more genomes per run and enabling higher-coverage cancer genome sequencing.

The SOLiD Microfluidic FlowChip allows one to six independent lanes to be run with two FlowChips. For rapid turnaround, time a single lane can be completed in one day. The FlowChip uses very low volumes of sequencing reagents, allowing high throughput users to realize an initial cost of as little as US$3,000 per genome.

The 5500xl is a robust benchtop instrument with an integrated monitor and desktop computer. It contains a robotic reagent delivery system to track usage and provide quality checkpoints across the entire workflow, leaving little room for errors. Real-time data processing removes the need for a compute cluster and reduces the data footprint, speeding time to result and simplifying data handling.

The SOLiD 4hq and SOLiD PI programs were combined to develop a single, robust, easy-to-use platform for all researchers. Current SOLiD 4 system customers will be offered a cost-effective path to step up to the higher throughput 5500xl system. The SOLiD PI system will be replaced by the affordable 5500 SOLiD sequencer.

The 5500 and 5500xl SOLiD sequencers are for research use only, and not intended for animal or human therapeutic or diagnostic use.

Related Links:
Life Technologies
Hitachi High-Technologies


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
Laboratory Electric Thermostat
DNP-9025A
New
Urine Collection Container
Urine Monovette

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.